Ophthalmology Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, France, Japan - Size and Forecast 2024-2028

Published: Dec 2023

Pages: 178

SKU: IRTNTR40882

Snapshot

Ophthalmology Therapeutics Market 2024-2028

The global ophthalmology therapeutics market size is estimated to grow by USD 18.15 billion at a CAGR of 6.78% between 2023 and 2028.

The prevalence of eye diseases is rising which has led to an increase in approvals for novel drugs for the treatment of various eye diseases, such as degenerative macular edema, glaucoma, dry eye syndrome, and eye infections. Market players are developing therapeutics that offer higher safety and efficacy in treating such diseases. For instance, in September 2022, Harrow Health, Inc. announced that the US FDA had approved Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. Moreover, the increase in the development of therapeutics to treat various eye diseases will contribute to market growth during the forecast period.

Technavio has segmented the market into Type, Product, and Geography

The type segment includes prescription drugs and OTC drugs
The product segment includes retinal disorder therapeutics, glaucoma therapeutics, dry eye disease therapeutics, eye infections and inflammation therapeutics, and others
The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Besides analyzing the current market scenario, our report examines historical data from 2018-2022.

What will be the Size of the Ophthalmology Therapeutics Market During the Forecast Period?

To learn more about this report, Download Report Sample

Ophthalmology Therapeutics Market Segmentation by Type, Product, and GeographyAnalysis

Type Analysis

Prescription drugs

The market share growth by the prescription drugs segment will be significant during the forecast period. A prescription drug requires a prescription to be legally dispensed, unlike over-the-counter (OTC) drugs that can be obtained without any prescription. The main reason behind the control is the possible misuse of the drug or its strictly regulated use. Prescription drugs indicated for treating ophthalmologic diseases are finding significant adoption among patients with chronic ophthalmologic disorders.

Get a glance at the market contribution of various segments Download PDF Sample

The prescription drugs segment was valued at USD 21.94 billion in 2018. In addition, prescription drugs for dry eyes are more expensive than OTC versions. Consequently, the adoption of prescription drugs is limited. However, the increasing prevalence of chronic ophthalmologic conditions and the emergence of new drugs are expected to fuel the growth of the prescription drugs segment and drive the global ophthalmology therapeutics market during the forecast period.

Product Analysis

Retinal disorder therapeutics

The major retinal diseases include age-related macular degeneration, diabetic eye disease, retinal vein occlusion, macular edema, posterior vitreous detachment, retinal dystrophy, and RPE65 mutation-associated inherited retinal disease. The high incidence of retinal disorders, as well as the presence of approved retinal disorder therapeutics, are driving the segment's growth. Furthermore, the increasing necessity of therapeutics with high efficacy and safety has led to an increase in the R&D of novel therapeutics for age-related macular degeneration. Besides, the availability of symptomatic and curative therapies for the treatment of retinal disorders will drive the growth of the retinal disorder therapeutics segment and boost the growth of the market during the forecast period.

Glaucoma therapeutics

Glaucoma is a disease that damages the optic nerve in the eye. Primary open-angle glaucoma is the most common type of glaucoma worldwide. The most commonly used glaucoma drugs are selective alpha 2 agonists such as brimonidine (0.1%, 0.15%, and 0.2%) and apraclonidine (0.5% and 1%), which reduce intraocular pressure by suppressing the production of aqueous humor. Furthermore, the percentage of people with glaucoma worldwide is expected to increase from 0.10% in 2020 to 1.12% in 2040. The disease mainly affects the elderly population. Therefore, the increasing aging population will also lead to an increase in the prevalence of glaucoma. The approval of therapeutics that treat glaucoma will further drive market growth during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 44% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers will shape the market during the forecast period. North America holds the largest share of the market, primarily due to the strong prevalence of eye diseases such as age-related macular degeneration, glaucoma, dry eye, and various eye infections.

Furthermore, the rising incidence of risk factors such as prolonged use of corticosteroids, diabetes, a family history of eye diseases, previous eye injuries or eye surgeries, and extended exposure to sunlight are also major factors responsible for the high prevalence of eye diseases in the region. Such growth in the prevalence of eye disorders has led to an increase in various initiatives that aim at making the public aware of eye diseases. Hence, such factors are expected to drive market growth in this region during the forecast period.

Buy Full Report Now

Key Ophthalmology Therapeutics Market Players

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

AbbVie Inc.: The company offers ophthalmology therapeutics such as VUITY which provides pilocarpine hydrochloride opthlmic solution that is used to treat age related blurry near vision in adults.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Ophthalmology Therapeutics Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.

Key Ophthalmology Therapeutics Market Drivers

The increase in the prevalence of eye diseases is the key factor driving market growth. The growing aging population is a major factor contributing to the increase in the prevalence of age-related macular degeneration. Similarly, the incidence of diabetic retinopathy, diabetic macular edema, and retinal vein occlusion, which are complications of diabetes that affect the eyes, has also increased worldwide. Retinal vein occlusion is a common vascular disorder of the retina and one of the most common causes of blindness globally. After diabetic retinopathy, it is the second-most common cause of vision loss.

Furthermore, glaucoma is another eye condition that can damage the optic nerve and lead to the development of eye diseases. It is the second-most common cause of vision loss worldwide after cataracts. However, unlike cataracts, the vision loss associated with glaucoma is largely irreversible. The prevalence of glaucoma has increased worldwide. Therefore, the rise in the prevalence of eye diseases has led to an increase in demand for ophthalmology therapeutics, thereby driving market growth during the forecast period

Significant Ophthalmology Therapeutics Market Trends

An increase in strategic alliances is the primary trend shaping market growth. The strategic collaborations are expected to increase the shares of the ophthalmology therapeutics market players. Market players also opt for collaborations as a business strategy to expand their product portfolios and strengthen their businesses. For instance, in July 2022, Avista Therapeutics partnered with F. Hoffmann-La Roche AG to develop novel adeno-associated virus gene therapy vectors for rare ophthalmic conditions.

Similarly, in October 2022, Charles River Laboratories International, Inc. and Nanoscope Therapeutics, Inc. announced a strategic collaboration for contract development and manufacturing of both plasmid DNA and viral vectors used in gene therapies for retinal degenerative diseases. Hence, such partnerships and collaborations among the companies offering ophthalmology therapeutics is likely to boost market growth during the forecast period.

Major Ophthalmology Therapeutics Market Challenges

The expiry of patents of ophthalmology therapeutics is a challenge that affects market growth. The entry of generic versions of ophthalmology drugs after patent expiry introduces increased competition. Generic drugs are often more affordable, leading to potential market share shifts as patients and healthcare providers may opt for cost-effective alternatives. The expiration of patents can lead to a decline in revenue for the original manufacturers of ophthalmology therapeutics as generic alternatives enter the market and capture a portion of sales.

Moreover, in the case of biologic ophthalmology therapeutics, the expiration of patents may open opportunities for the development and entry of biosimilar products, which are similar but not identical to the originator biologics. For instance, the patent on LUCENTIS expired in 2020 in the US, and it is expected to expire in the European Union in 2025. Thus, the expiration of patents for ophthalmology therapeutics will impede the growth of the market in focus during the forecast period.

Buy Now Full Report

Key Ophthalmology Therapeutics Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Ophthalmology Therapeutics Market Customer Landscape

Segment Overview

The ophthalmology therapeutics market report forecasts market growth by revenue at global, regional & country levels and analyzes the latest trends and growth opportunities from 2018 to 2028.

Type Outlook
- Prescription drugs
- OTC drugs

Product Outlook
- Retinal disorder therapeutics
- Glaucoma therapeutics
- Dry eye disease therapeutics
- Eye infections and inflammation therapeutics
- Others

Region Outlook
- North America
  - The U.S.
  - Canada
- Europe
  - The U.K.
  - Germany
  - France
  - Rest of Europe
- Asia
  - China
  - India
- Rest of the World (ROW)
  - Brazil
  - Argentina
  - Australia

Ophthalmology Therapeutics Market Scope
Report Coverage	Details
Page number	178
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 6.78%
Market Growth 2024-2028	USD 18.15 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	5.71
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 44%
Key countries	US, Germany, UK, France, and Japan
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	AbbVie Inc., Adrif Vision, Alcon Inc., Aldeyra Therapeutics Inc., Alembic Pharmaceuticals Ltd., Avellino Lab USA Inc, Bausch Health Companies Inc., Bayer AG, Boehringer Ingelheim International GmbH, Charles River Laboratories International Inc., Cyagen Biosciences, ENTOD INTERNATIONAL, Eyenovia Inc., Eyeris Vision Care Pvt. Ltd., F. Hoffmann La Roche Ltd., Grevis Pharmaceuticals Pvt. Ltd., Harrow Health Inc, Johnson and Johnson, Laboratoires THEA SAS, MeiraGTx Holdings Plc., Nanoscope Therapeutics Inc., Novaliq GmbH, Novartis AG, Ocular Therapeutix Inc., Oculis Holding AG, Otsuka Holdings Co. Ltd., Oxurion N, Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., SISAF LTD, Sun Pharmaceutical Industries Ltd., Surrozen Inc., Swissvision, TearSolutions Inc., Teva Pharmaceutical Industries Ltd., THINKCYTE Inc., Vee Remedies, Vision Care Inc., Visufarma, Visus Therapeutics Inc., Evotec SE, and Prestige Consumer Healthcare Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Ophthalmology Therapeutics Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the ophthalmology therapeutics market between 2024 and 2028
Precise estimation of the ophthalmology therapeutics market size and its contribution to the market in focus on the parent market
Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria
Companies landscape comparing criticality of inputs and factors of differentiation
Exclusive Matrix on companies' position and classification
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
A thorough analysis of the market’s competitive landscape and detailed information about companies
Comprehensive analysis of factors that will challenge the growth of ophthalmology therapeutics market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Product
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2023

3.4 Market outlook: Forecast for 2023-2028
- Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
- Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global ophthalmology therapeutics market 2018 - 2022
- Exhibit 18: Historic Market Size – Data Table on global ophthalmology therapeutics market 2018 - 2022 ($ billion)

4.2 Type Segment Analysis 2018 - 2022
- Exhibit 19: Historic Market Size – Type Segment 2018 - 2022 ($ billion)

4.3 Product Segment Analysis 2018 - 2022
- Exhibit 20: Historic Market Size – Product Segment 2018 - 2022 ($ billion)

4.4 Geography Segment Analysis 2018 - 2022
- Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)

4.5 Country Segment Analysis 2018 - 2022
- Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2023 and 2028

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Type

6.1 Market segments
- Exhibit 30: Chart on Type - Market share 2023-2028 (%)
- Exhibit 31: Data Table on Type - Market share 2023-2028 (%)

6.2 Comparison by Type
- Exhibit 32: Chart on Comparison by Type
- Exhibit 33: Data Table on Comparison by Type

6.3 Prescription drugs - Market size and forecast 2023-2028
- Exhibit 34: Chart on Prescription drugs - Market size and forecast 2023-2028 ($ billion)
- Exhibit 35: Data Table on Prescription drugs - Market size and forecast 2023-2028 ($ billion)
- Exhibit 36: Chart on Prescription drugs - Year-over-year growth 2023-2028 (%)
- Exhibit 37: Data Table on Prescription drugs - Year-over-year growth 2023-2028 (%)

6.4 OTC drugs - Market size and forecast 2023-2028
- Exhibit 38: Chart on OTC drugs - Market size and forecast 2023-2028 ($ billion)
- Exhibit 39: Data Table on OTC drugs - Market size and forecast 2023-2028 ($ billion)
- Exhibit 40: Chart on OTC drugs - Year-over-year growth 2023-2028 (%)
- Exhibit 41: Data Table on OTC drugs - Year-over-year growth 2023-2028 (%)

6.5 Market opportunity by Type
- Exhibit 42: Market opportunity by Type ($ billion)
- Exhibit 43: Data Table on Market opportunity by Type ($ billion)

7 Market Segmentation by Product

7.1 Market segments
- Exhibit 44: Chart on Product - Market share 2023-2028 (%)
- Exhibit 45: Data Table on Product - Market share 2023-2028 (%)

7.2 Comparison by Product
- Exhibit 46: Chart on Comparison by Product
- Exhibit 47: Data Table on Comparison by Product

7.3 Retinal disorder therapeutics - Market size and forecast 2023-2028
- Exhibit 48: Chart on Retinal disorder therapeutics - Market size and forecast 2023-2028 ($ billion)
- Exhibit 49: Data Table on Retinal disorder therapeutics - Market size and forecast 2023-2028 ($ billion)
- Exhibit 50: Chart on Retinal disorder therapeutics - Year-over-year growth 2023-2028 (%)
- Exhibit 51: Data Table on Retinal disorder therapeutics - Year-over-year growth 2023-2028 (%)

7.4 Glaucoma therapeutics - Market size and forecast 2023-2028
- Exhibit 52: Chart on Glaucoma therapeutics - Market size and forecast 2023-2028 ($ billion)
- Exhibit 53: Data Table on Glaucoma therapeutics - Market size and forecast 2023-2028 ($ billion)
- Exhibit 54: Chart on Glaucoma therapeutics - Year-over-year growth 2023-2028 (%)
- Exhibit 55: Data Table on Glaucoma therapeutics - Year-over-year growth 2023-2028 (%)

7.5 Dry eye disease therapeutics - Market size and forecast 2023-2028
- Exhibit 56: Chart on Dry eye disease therapeutics - Market size and forecast 2023-2028 ($ billion)
- Exhibit 57: Data Table on Dry eye disease therapeutics - Market size and forecast 2023-2028 ($ billion)
- Exhibit 58: Chart on Dry eye disease therapeutics - Year-over-year growth 2023-2028 (%)
- Exhibit 59: Data Table on Dry eye disease therapeutics - Year-over-year growth 2023-2028 (%)

7.6 Eye infections and inflammation therapeutics - Market size and forecast 2023-2028
- Exhibit 60: Chart on Eye infections and inflammation therapeutics - Market size and forecast 2023-2028 ($ billion)
- Exhibit 61: Data Table on Eye infections and inflammation therapeutics - Market size and forecast 2023-2028 ($ billion)
- Exhibit 62: Chart on Eye infections and inflammation therapeutics - Year-over-year growth 2023-2028 (%)
- Exhibit 63: Data Table on Eye infections and inflammation therapeutics - Year-over-year growth 2023-2028 (%)

7.7 Others - Market size and forecast 2023-2028
- Exhibit 64: Chart on Others - Market size and forecast 2023-2028 ($ billion)
- Exhibit 65: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
- Exhibit 66: Chart on Others - Year-over-year growth 2023-2028 (%)
- Exhibit 67: Data Table on Others - Year-over-year growth 2023-2028 (%)

7.8 Market opportunity by Product
- Exhibit 68: Market opportunity by Product ($ billion)
- Exhibit 69: Data Table on Market opportunity by Product ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 71: Chart on Market share by geography 2023-2028 (%)
- Exhibit 72: Data Table on Market share by geography 2023-2028 (%)

9.2 Geographic comparison
- Exhibit 73: Chart on Geographic comparison
- Exhibit 74: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2023-2028
- Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ billion)
- Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
- Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%)
- Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%)

9.4 Europe - Market size and forecast 2023-2028
- Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
- Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
- Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%)
- Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%)

9.5 Asia - Market size and forecast 2023-2028
- Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
- Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
- Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%)
- Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%)

9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)

9.7 US - Market size and forecast 2023-2028
- Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ billion)
- Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ billion)
- Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%)
- Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%)

9.8 Germany - Market size and forecast 2023-2028
- Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
- Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
- Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
- Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)

9.9 UK - Market size and forecast 2023-2028
- Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
- Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
- Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
- Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)

9.10 France - Market size and forecast 2023-2028
- Exhibit 103: Chart on France - Market size and forecast 2023-2028 ($ billion)
- Exhibit 104: Data Table on France - Market size and forecast 2023-2028 ($ billion)
- Exhibit 105: Chart on France - Year-over-year growth 2023-2028 (%)
- Exhibit 106: Data Table on France - Year-over-year growth 2023-2028 (%)

9.11 Japan - Market size and forecast 2023-2028
- Exhibit 107: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
- Exhibit 108: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
- Exhibit 109: Chart on Japan - Year-over-year growth 2023-2028 (%)
- Exhibit 110: Data Table on Japan - Year-over-year growth 2023-2028 (%)

9.12 Market opportunity by geography
- Exhibit 111: Market opportunity by geography ($ billion)
- Exhibit 112: Data Tables on Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 113: Impact of drivers and challenges in 2023 and 2028

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 114: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 115: Overview on factors of disruption

11.4 Industry risks
- Exhibit 116: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 117: Vendors covered

12.2 Market positioning of vendors
- Exhibit 118: Matrix on vendor position and classification

12.3 AbbVie Inc.
- Exhibit 119: AbbVie Inc. - Overview
- Exhibit 120: AbbVie Inc. - Product / Service
- Exhibit 121: AbbVie Inc. - Key news
- Exhibit 122: AbbVie Inc. - Key offerings

12.4 Aldeyra Therapeutics Inc.
- Exhibit 123: Aldeyra Therapeutics Inc. - Overview
- Exhibit 124: Aldeyra Therapeutics Inc. - Product / Service
- Exhibit 125: Aldeyra Therapeutics Inc. - Key offerings

12.5 Bausch Health Companies Inc.
- Exhibit 126: Bausch Health Companies Inc. - Overview
- Exhibit 127: Bausch Health Companies Inc. - Business segments
- Exhibit 128: Bausch Health Companies Inc. - Key news
- Exhibit 129: Bausch Health Companies Inc. - Key offerings
- Exhibit 130: Bausch Health Companies Inc. - Segment focus

12.6 Bayer AG
- Exhibit 131: Bayer AG - Overview
- Exhibit 132: Bayer AG - Business segments
- Exhibit 133: Bayer AG - Key news
- Exhibit 134: Bayer AG - Key offerings
- Exhibit 135: Bayer AG - Segment focus

12.7 F. Hoffmann La Roche Ltd.
- Exhibit 136: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 137: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 138: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 139: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 140: F. Hoffmann La Roche Ltd. - Segment focus

12.8 Novartis AG
- Exhibit 141: Novartis AG - Overview
- Exhibit 142: Novartis AG - Business segments
- Exhibit 143: Novartis AG - Key offerings
- Exhibit 144: Novartis AG - Segment focus

12.9 Ocular Therapeutix Inc.
- Exhibit 145: Ocular Therapeutix Inc. - Overview
- Exhibit 146: Ocular Therapeutix Inc. - Product / Service
- Exhibit 147: Ocular Therapeutix Inc. - Key offerings

12.10 Otsuka Holdings Co. Ltd.
- Exhibit 148: Otsuka Holdings Co. Ltd. - Overview
- Exhibit 149: Otsuka Holdings Co. Ltd. - Business segments
- Exhibit 150: Otsuka Holdings Co. Ltd. - Key offerings
- Exhibit 151: Otsuka Holdings Co. Ltd. - Segment focus

12.11 Oxurion N
- Exhibit 152: Oxurion N - Overview
- Exhibit 153: Oxurion N - Product / Service
- Exhibit 154: Oxurion N - Key offerings

12.12 Pfizer Inc.
- Exhibit 155: Pfizer Inc. - Overview
- Exhibit 156: Pfizer Inc. - Product / Service
- Exhibit 157: Pfizer Inc. - Key news
- Exhibit 158: Pfizer Inc. - Key offerings

12.13 Regeneron Pharmaceuticals Inc.
- Exhibit 159: Regeneron Pharmaceuticals Inc. - Overview
- Exhibit 160: Regeneron Pharmaceuticals Inc. - Product / Service
- Exhibit 161: Regeneron Pharmaceuticals Inc. - Key offerings

12.14 Santen Pharmaceutical Co. Ltd.
- Exhibit 162: Santen Pharmaceutical Co. Ltd. - Overview
- Exhibit 163: Santen Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 164: Santen Pharmaceutical Co. Ltd. - Key offerings

12.15 Sun Pharmaceutical Industries Ltd.
- Exhibit 165: Sun Pharmaceutical Industries Ltd. - Overview
- Exhibit 166: Sun Pharmaceutical Industries Ltd. - Product / Service
- Exhibit 167: Sun Pharmaceutical Industries Ltd. - Key offerings

12.16 Teva Pharmaceutical Industries Ltd.
- Exhibit 168: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 169: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 170: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 171: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 172: Teva Pharmaceutical Industries Ltd. - Segment focus

12.17 Visufarma
- Exhibit 173: Visufarma - Overview
- Exhibit 174: Visufarma - Product / Service
- Exhibit 175: Visufarma - Key offerings

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 176: Inclusions checklist
- Exhibit 177: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 178: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 179: Research methodology
- Exhibit 180: Validation techniques employed for market sizing
- Exhibit 181: Information sources

13.5 List of abbreviations
- Exhibit 182: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

ophthalmology therapeutics market market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis